<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; advantages</title>
	<atom:link href="http://www.tapanray.in/tag/advantages/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Would ‘Complex Generics’ Attract More ‘Authorized Generics’?</title>
		<link>http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-complex-generics-attract-more-authorized-generics</link>
		<comments>http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/#comments</comments>
		<pubDate>Mon, 28 Oct 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[authorized]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[speciality]]></category>
		<category><![CDATA[spoilsport]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9761</guid>
		<description><![CDATA[Despite increasing numbers of alleged scams involving generic drugs, both in the United States and also in India, even involving many large generic drug manufacturers, the traditional generic drug market, keeps growing globally. Although, the current growth is in mid-single &#8230; <a href="http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘e-detailing’: The Future of Pharmaceutical Sales?</title>
		<link>http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=e-detailing-the-future-of-pharmaceutical-sales</link>
		<comments>http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/#comments</comments>
		<pubDate>Sun, 29 Sep 2013 23:30:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[askpfizer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[effectiveness]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[japanese]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pfizerline]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3751</guid>
		<description><![CDATA[Pharmaceutical product detailing to doctors by Medical Representatives (MRs) is believed to fetch the single largest return on marketing investments by the pharmaceutical companies globally, as on date. At the same time, the pharma players, across the world, are increasingly &#8230; <a href="http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India as a global pharmaceutical outsourcing hub: Some key advantages and the areas of improvement.</title>
		<link>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement</link>
		<comments>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/#comments</comments>
		<pubDate>Mon, 04 Jan 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[hub]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=488</guid>
		<description><![CDATA[All over the world, pharmaceutical research and development pipelines are gradually getting dried up. Lesser and lesser blockbuster drugs are now coming up from the ‘mind to the market’. Currently the average annual turnover of over 90% of patented drugs &#8230; <a href="http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
